The latest Business updates from the science industry
UK Companies Partner On COVID-19 Antibody Test by Heather Hobbs
Mologic’s COVID-19 lateral fl ow test has been combined with a kit designed by BioSure to create a COVID-19 antibody self-test that can be used without any training. Requiring only a fraction of a drop of blood, gives the user their own result in just 10 minutes.
The BioSURE COVID-19 Antibody Self-Test, expected to be ready for mass production at the beginning of June, will be available to the UK and global markets and for direct purchase.
Mark Davis, CEO, Mologic said: “Mologic is thrilled to be partnering with BioSure on this COVID-19 self-test, which will enable people to quickly and safely test for antibodies to the virus in their own home. The team and our independent validation partners have worked tirelessly to develop and optimise this quality rapid diagnostic in record time and this partnership brings it one step closer getting it on the market. To all those that have contributed to this project and supported us thus far, I offer my sincere gratitude.”
Brigette Bard, CEO of BioSure added: “We are incredibly proud to announce our partnership with Mologic, the world-leading scientifi c researchers. Our companies are very aligned in their dynamic thinking and the way we both have a strong passion to fi nd solutions to problems. Their expertise and creativity mean that together we have an outstanding test, that everyone, everywhere, will be able to test on their own terms. I cannot thank them enough for their phenomenal approach and extraordinary hard work and I would also like to thank the general public for their unwavering support. Our companies have already developed life-saving diagnostics across our individual product portfolios, including HIV and Ebola, and jointly
Mark Davies
we can now continue to accelerate our impact by putting the test into the end users’ hands, who will get their own result while they wait.”
Brigette Bard
52228pr@reply-direct.com
University of Pittsburgh Wins DeNovix Automated Cell Counter Competition
fl uorescent cell quantifi cation. We think the CellDrop FL will really help their research workfl ows.”
DeNovix Inc is pleased to announce that the winner of their recent competition to receive a donation of a unique, pink CellDrop Automated Cell Counter is Beth Kahkonen, from the University of Pittsburgh, USA. Selected at random from thousands of entries from scientists worldwide, the CellDrop will be housed in the University’s Division of Pulmonary, Allergy, and Critical Care Medicine.
CellDrop Automated Cell Counters feature unique DirectPipette™ Technology, a novel sample loading method that eliminates the need for disposable plastic slides typically required for routine cell counting.
“We are delighted that Beth will be receiving our Pink CellDrop,” commented Kevin Kelley, Business Director at DeNovix. “It’s great that the winning lab can retire their hemocytometer and move away from manual counts. Their applications need both brightfi eld and
“We are thrilled to have won the CellDrop,” said Beth Kahkonen. “Researchers in our immediate lab will save time counting cells from culture and primary sources. At the end of a long day of harvesting mouse organs and tissues, it is always exhausting to have to then count cells from each sample with the hemocytometer. It will also help us to effi ciently and accurately count live versus dead cells for tissue culture experiments and should make our experiments more reproducible instead of relying on manual user counts. We tried out the CellDrop this week and fi nd it very easy and convenient to use. It is also notable that the user guide is installed on the device itself, so one can readily fi nd answers to user questions. Researchers from other labs in our division will also be glad to use the automated cell counter. I believe everyone in our division will benefi t from having access to this technology. We look to forward to exploring the variety of applications the CellDrop has to offer. Thank you DeNovix!”
The CellDrop features both dual fl uorescence and brightfi eld optics and a variable height chamber, enabling accurate measurement across a wide range of cell types, densities and sizes. The proprietary sample measurement system, inheriting a familiar load, count and wipe clean procedure from the award-winning DS-11 Series spectrophotometers/fl uorometers eliminates the need for disposable slides or hemocytometers. Additionally, its easy-to-use software and 7” touchscreen interface and network integration, enable users to capture, review and export data easily and securely.
More information online:
ilmt.co/PL/nAEE 52481pr@reply-direct.com
Acquisition Enhances Potential for pre- Clinical Services
Integrated drug discovery and pre-clinical services company Sygnature Discovery has expanded its oncology and immuno- oncology capabilities with the acquisition of Alderley Oncology, a focused in vivo pharmacology service provider which undertakes high quality in vivo services for biotechs, pharmaceutical companies and academics. Prior to the take-over Alderley Oncology was run by Bruntwood SciTech, owners of Alderley Park. The value of the deal has not been disclosed.
Alderley Oncology was established by Jane Kendrew in 2017. Jane and the team have a wealth of experience in the fi eld, much of it gained at AstraZeneca. “We are delighted to be joining Sygnature Discovery,” she said. “We look forward to working with them as part of the wider team serving the oncology drug discovery community and patients living with cancer.’
“We are pleased to welcome Jane and her colleagues to Sygnature Discovery,” said Dr Stuart Onions, Director of Research Management at Sygnature. “The team’s expertise in oncology and immuno- oncology in vivo models will signifi cantly enhance our integrated oncology provision, delivering further value to our integrated projects for clients and importantly, allows us to more effi ciently and effectively deliver potential new therapeutics into pre-clinic development.”
The deal complements the 2018 acquisition of Nottingham-based RenaSci, which added complementary in vivo expertise in abuse and dependence, metabolic diseases, CNS disorders, and liver and kidney disease to Sygnature’s in vitro services.
52473pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
